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Figure 2.  A multinucleated giant 
cell is depicted in this high power 
magnification view of a 1-mo 
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Objective: To evaluate the potential for 
injectable, permanent bone 
augmentation by assessing the 
biocompatibility and bioactivity of 
subperiosteal hydroxylapatite (Radiesse) 
deposition in a rat model. 
 
Methods: Fourteen adult Sprague 
Dawley rats were injected in the parietal 
skull with hydroxylapatite (n=10) or a 
carrier gel control (n=4), using a 
subperiosteal injection technique on the 
right and a subcutaneous injection 
technique on the left.  At 1, 3, and 6 
months, 3 rats (1 negative control, 2 
variables) were sacrificed.   At 12 
months, the remaining 5 rats were 
sacrificed.  After each harvest, the 
calvaria were examined under both light 
and polarized microscopy. 
 
Results: The inflammatory response was 
limited in all specimens.  Injectables 
were still present 12 months after the 
injection.  New bone formation was only 
seen when the injection was located 
deep to a disrupted periosteum  The odd 
of new bone formation was 48.949 times 
higher (95% CI (2.637, 3759.961), p = 
0.002) with subperiosteal hydroxylapatite 
injections compared to all other 
combinations of injection plane and 
injectable. 
 
Conclusion: This preliminary report of 
subperiosteal hydroxylapatite (Radiesse) 
injection in a rat model has verified the 
biocompatibility of injectable 
hydroxylapatite at the bony interface and 
suggests the potential for new bone 
formation. 
 Histologic data are summarized in Table 1. While 
multinucleated giant cells were often present (Figure 2), 
only minimal fibrosis was noted in the specimens. Seven 
(2 carrier, 5 HA) out of 13 “subperiosteal” injections were 
found to be deep to a disrupted periosteum, while the 
remaining 6 were noted to be in the subcutaneous layer 
with an intact periosteum beneath.  Of note, HA spherules 
could not be found at the subcutaneous site for specimen 
12 and at both injection sites for specimen 13. 
  
  Reactive bone was not seen in the absence of 
periosteal disruption.  In 1 of 2 rats with successful 
subperiosteal carrier injections, reactive bone was present 
at the time of harvest.  This rat, specimen 7, was 
sacrificed at 6 months (Figure 3).  Reactive bone was 
observed with subperiosteal HA injections in 4 out of 5 
rats- specimen 2 from the 1 month harvest (Figure 4), 
specimen 5 from the 3 month harvest, and specimens 12 
and 14 from the 12 month harvest.  Interestingly, mature 
lamellar bone was seen above the HA spherules in 
specimen 12, indicating osteointegration.  (Figure 5) 
 Minor deformities of the craniofacial skeleton can be 
quite bothersome aesthetically to patients.  Radiesse 
provides an intriguing option for these patients as its main 
biologic constituent, HA, has been used for over 2 decades 
in other formulations for open craniofacial reconstruction.2  
FDA-approved for the treatment of HIV-related lipoatrophy 
and moderate to deep nasolabial folds, Radiesse is well-
established in facial plastic surgery for soft tissue 
augmentation.3,4  Over the years, various studies have 
confirmed its safety, longevity and bioactivity (specifically 
the stimulation of new collagen deposition) when injected 
subcutaneously.5-7  Not surprisingly, off label uses of 
Radiesse have arisen as well.8-10  
 
 To our knowledge, no one to date has examined the 
histologic effects of Radiesse injection at the bony interface.  
We have now shown that Radiesse is biocompatible and 
long-lasting subperiosteally.  In designing the study, we did 
consider the fact that the trauma of periosteal disruption 
could trigger osteoactivity and therefore confound results.  
We attempted to control for this with the carrier only 
injections; hypothesizing that new bone formation would be 
either absent or less pronounced without HA.  
Unfortunately, our technique for periosteal disruption was 
only successful 54% of the time.  Consequently, the 
numbers for truly subperiosteal HA and carrier injections 
were simply too low to demonstrate a statistically significant 
difference in the rate of new bone formation between the 
two.  Notably, though, the odd of new bone formation in the 
subperiosteal HA injection group was significantly higher 
than the aggregate of all other combinations of injection 
plane and injectable.  We were also able to show that the 
plane of injection seems to be critical in any effort to induce 
osteoactivity as none of the subcutaneous injections 
resulted in new bone formation.  Lastly, our observations 
suggest that, regardless of the mechanism triggering new 
bone formation, injectable HA can be osteointegrated. 
 
 Refinements in the technique for subperiosteal 
injection are clearly necessary, and further study on a larger 
scale is warranted to better elucidate the stimulus for the 
osteoactivity we observed histologically.  
 Fourteen adult Sprague Dawley rats were injected 
in the parietal skull with 0.2 ml of HA (n=10) or a carrier 
gel control (n=4).  In each rat, the left sided injection was 
performed just medial to the auricle with a 23-gauge 
needle in a subcutaneous plane.  On the right side of the 
calvarium, a 20-gauge needle was first employed to 
elevate the periosteum, and then a 23-gauge needle was 
used to inject the material directly on to the underlying 
bone (again just medial to the auricle).   
 
 Animals were subsequently sacrificed at 4 time 
points (1,3,6, and 12 months after the initial injections) 
and calvaria were harvested for histologic analysis.  Each 
of the first 3 harvests included 2 rats from the HA group 
and 1 negative control from the carrier gel group.  The 
12-month harvest again included 1 negative control as 
well as the remaining 4 rats from the HA group.  All 
specimens were stained with hematoxylin and eosin.  
Under low power magnification, the injectables were 
located and the surrounding tissue was examined.  
Proper identification of the injectables was confirmed by 
examining and comparing separate samples of the HA 
and carrier gel ex vivo (Figure 1).  Polarized microscopy 
was used to distinguish new (woven) bone from mature 
(lamellar) bone.  
 
 Odds ratios, p values and 95% confidence 
intervals (CI) were calculated using Fisher’s conditional 
maximum likelihood estimation.  P values < 0.05 were 
considered significant. 
 Presently, calcium phosphate cements (CPC), 
such as hydroxylapatite (HA), are commonly used for the 
alloplastic repair of skull defects.  Favorable 
characteristics of CPC include customizability, isothermic 
setting, biocompatibility, and bioactivity (resorption is 
countered by new bone replacement).1  Because of the 
chemical properties pertaining to setting, open exposure 
is required to use CPC effectively, and thus the 
application of CPC is reserved for large defects, such as 
those that result from tumor extirpation or extensive 
trauma.  However, facial plastic surgeons are often faced 
with smaller craniofacial deformities that are of aesthetic 
concern to the patient but do not warrant the morbidity of 
open surgery.  Examples would include relatively minor 
traumatic bony injury and contour deficiencies from prior 
surgery.  With these defects in mind, the present study 
was designed to examine the biologic characteristics of 
injectable HA when interfaced with bone. 
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 In an attempt to analyze the effect of the injection 
plane (subcutaneous vs subperiosteal) and the injectable 
(carrier vs HA) on new bone formation, histologic data 
was re-organized as depicted in Table 2.  Of note, 
injections that were intended to be subperiosteal but 
were found to be subcutaneous on histologic review were 
considered “subcutaneous” (n=6) for the purposes of 
statistical analysis.  Furthermore, any specimen without 
an identifiable injectable (subcutaneous injection site in 
specimen 12 and both sites in specimen 13) were 
excluded.   
 
 The odd of new bone formation in the 
subperiosteal HA injection group was 48.949 times 
higher than the other 3 combinations in aggregate (95% 
CI (2.637, 3759.961), p = 0.002).  The marginal effect of 
subperiosteal injection was also significant, but a discrete 
odds ratio could not be computed due to the zero-count 
cells in the subcutaneous groups (95% CI (4.068, 
infinity), p < 0.001).  The marginal effect of HA, however, 
was not significant.   
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Figure 1. Amorphous carrier gel (A) and hydroxylapatite 
spherules (B) shown under high power magnification 
Figure 3. Under low power, 
subperiosteal carrier is noted to 
be embedded in new, woven 
bone in this 6-mo specimen 
Figure 4. Under high power, new 
bone formation is seen amidst 
suboeriosteal hydroxylapatite 
spherules in this 1-mo specimen 
Figure 5. Under high power, 
hydroxylapatite spherules from 
this 12-mo specimen appear 
osteointegrated 
Table 1. Summary of binary histologic data.  The 
presence of periosteal disruption and new bone formation 
is indicated with a (+).  HA = hydroxylapatite (Radiesse) 
Table 2. Summary of binary data for rate of new bone 
formation, grouped by all combinations of injection plane 
and injectable.  SC=subcutaneous, SP=subperiosteal, 
HA=hydroxylapatite (Radiesse) 
